



ASX Announcement

Section 708A Cleansing Statement

Melbourne, Australia; 28 July 2026:

This notice is given by Lumos Diagnostics Holdings Limited Ltd (ASX: LDX) (**Company**) under Section 708A(5)(e) of the *Corporations Act 2001* (Cth) (**Corporations Act**).

The Company hereby confirms that:

- (a) It has issued 36,821 Fully Paid Ordinary Shares (Shares) on exercise of unquoted options held by an employee of the Company exercisable at \$0.0576.
- (b) It has issued 394,408 Fully Paid Ordinary Shares (Shares) as the result of the cashless exercise of unquoted options held by employees of the Company;
- (c) the Shares referred to in paragraphs (a) and (b) above were issued without disclosure to investors under Part 6D.2 of the Corporations Act;
- (d) the Company is providing this notice under paragraph 5(e) of section 708A of the Corporations Act;
- (e) as at the date of this notice the Company, as a disclosing entity under the Corporations Act, has complied with:
 - (i) the provisions of Chapter 2M of the Corporations Act as they apply to the Company; and
 - (ii) section 674 of the Corporations Act as it applies to the Company; and
- (f) as at the date of this announcement, there is no excluded information of the type referred to in Sections 708A(7) and 708A(8) of the Corporations Act which is required to set out in this notice under Section 708A(6)(e) of the Corporations Act other than:
 - a. its annual report and financial statements for the financial year ended 30 June 2026 (2026 Annual Report) which is being prepared by the Company and will be released to the ASX on or before 31 August 2026. The Company confirms that the draft 2026 Annual Report as at the date of this cleansing notice does not contain any excluded information within the meaning of sections 708A(7) and 708A(8) of the Act which is required to be disclosed under section 708A(6)(e) of the Corporations Act.

<ENDS>

This announcement has been approved by the Lumos Disclosure Committee.

About Lumos Diagnostics

Lumos Diagnostics specialises in rapid, cost-effective, and complete point-of-care (POC) diagnostic test technology to help healthcare professionals more accurately diagnose and manage medical conditions. Lumos offers customised assay development and manufacturing services for POC tests and proprietary digital reader platforms. Lumos also directly develops, manufactures, and commercialises novel Lumos-branded POC tests that target infectious and inflammatory diseases.

For more information visit lumosdiagnostics.com or febridx.com.

**Forward-Looking Statements**

This announcement contains forward-looking statements, including references to forecasts. Forward-looking statements are not guarantees of future performance and involve known and unknown risks, uncertainties, assumptions, and other important factors, many of which are beyond Lumos' control and speak only as of the date of this announcement. Readers are cautioned not to place undue reliance on forward-looking statements.

Media Contacts:

Tom Trezona – Australia

HACK Director

tom@hck.digital

+61 (0) 411 235 692

Investor Contact:

George Kopsiaftis

Managing Director, IR Department

ir@lumosdiagnostics.com

+61 409 392 687

Company Registered Office:

Lumos Diagnostics Holdings Ltd

Suite 2, Level 11, 385 Bourke Street

Melbourne, VIC 3000

info@lumosdiagnostics.com

+61 3 9087 1598